Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

Michael Y. Choi, MD, Januario E. Castro, M.D., Sheila Hoff, RN, Hongying Li, PhD, Laura Rassenti, PhD, Danelle F. James, M.D., M.A.S., Karen Messer, PhD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 5299.

https://doi.org/10.1182/blood.V122.21.5299.5299

Published: 2013

Journal Articles

BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial

Manoj Kumar Kashyap, PhD, Carlos I. Amaya-Chanaga, MD, Harrison Jones, BS, Eiman A. AlMahasnah, MBBS, Michael Y. Choi, MD, Michelle R. Kuhne, PhD, Lewis Cohen, MD, MS, Peter Sabbatini, PhD, Thomas J. Kipps, MD, PhD, Pina M. Cardarelli, Ph.D., Januario E. Castro, M.D.

Blood (2013) 122 (21): 4190.

https://doi.org/10.1182/blood.V122.21.4190.4190

Published: 2013

Journal Articles

A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach

Deepak Kumar, PhD, Manoj Kumar Kashyap, PhD, Ide Spaanderman, BS, Reymundo Villa, PhD, Laura Rassenti, PhD, James La Clair, PhD, Michael D. Burkat, PhD, Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2013) 122 (21): 2884.

https://doi.org/10.1182/blood.V122.21.2884.2884

Published: 2013

Journal Articles

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

Manoj Kumar Kashyap, PhD, Deepak Kumar, PhD, Harrison Jones Jones, BS, Michael Y. Choi, MD, Johanna Melo-Cardenas, B.Sc, Michelle R. Kuhne, PhD, Peter Sabbatini, PhD, Lewis Cohen, MD, MS, Suresh Shelat, MD-PhD, Pina M Cardarelli, Ph.D., Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2012) 120 (21): 2887.

https://doi.org/10.1182/blood.V120.21.2887.2887

Published: 2012

Journal Articles

Fd-895 and Pladienolide B Inhibit mRNA Splicing and Induce Apoptosis in Chronic Lymphocytic Leukemia

Manoj Kumar Kashyap, PhD, Deepak Kumar, PhD, Harrison Jones Jones, BS, Maria Schwaederlé, PharmaD, Emanuela M. Ghia, PhD, Reymond Villa, PhD, James J La Clair, PhD, Michael D Burkart, PhD, Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2012) 120 (21): 3890.

https://doi.org/10.1182/blood.V120.21.3890.3890

Published: 2012

Journal Articles

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Januario E. Castro, M.D., Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Lina M. Ariza-Serrano, M.D. (c), Johanna Melo-Cardenas, B.Sc, Mauricio Rodriguez, D.D.S., M.S., Mauricio Urquiza, Ph.D., Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2544.

https://doi.org/10.1182/blood.V118.21.2544.2544

Published: 2011

Journal Articles

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma,

Caitlin L. Costello, MD, Peter Holman, MD, Margarida de Magalhaes-Silverman, MD, Sue Corringham, R.N., Januario E. Castro, M.D., Edward D. Ball, M.D.

Blood (2011) 118 (21): 4036.

https://doi.org/10.1182/blood.V118.21.4036.4036

Published: 2011

Journal Articles

Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia

Januario E. Castro, M.D., Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Lina M. Ariza-Serrano, M.D. (c), Sue Corringham, R.N., Thomas J. Kipps, M.D., Ph.D, Edward D. Ball, M.D.

Blood (2011) 118 (21): 4474.

https://doi.org/10.1182/blood.V118.21.4474.4474

Published: 2011

Journal Articles

Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia

Januario E. Castro, M.D., Lina M. Ariza-Serrano, M.D. (c), Juan S. Barajas-Gamboa, M.D., Julio A. Diaz-Perez, M.D., M.S., Danelle F. James, M.D., Amine Ale-Ali, Pharm.D., Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2866.

https://doi.org/10.1182/blood.V118.21.2866.2866

Published: 2011

Journal Articles

Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53

Michael Y. Choi, MD, Johanna Melo Cardenas, BSc, Desheng Lu, MD, PhD, Jian Yu, PhD, E. Paige Stout, PhD, Raymond P. Wu, Ph.D., John M Horton, B.S., Allison Gomez, Julio A. Diaz-Perez, M.D., M.S., Dennis A. Carson, M.D., Tadeusz F. Molinski, PhD, Thomas J. Kipps, M.D., Ph.D, Januario E. Castro, M.D.

Blood (2011) 118 (21): 1786.

https://doi.org/10.1182/blood.V118.21.1786.1786

Published: 2011

Journal Articles

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, M.D., Lee Schwartzberg, MD, FACP, Javier Pinilla-Ibarz, MD, PhD, Johanna Melo-Cardenas, B.Sc, Juan S. Barajas-Gamboa, M.D., Mark J. Cantwell, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 168.

https://doi.org/10.1182/blood.V118.21.168.168

Published: 2011

Journal Articles

Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

Januario E Castro, M.D, Juan Sebastian Barajas-Gamboa, M.D, Johanna Melo-Cardenas, B.Sc, Rosa N Paz, Cesar Bernal-Corzo, Amine Ale-Ali, Pharm., D., Danelle F. James, M.D, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 4638.

https://doi.org/10.1182/blood.V116.21.4638.4638

Published: 2010

Journal Articles

Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy

Danelle F. James, M.D., M.A.S., Jennifer R Brown, MD, PhD, Lillian Werner, Januario E Castro, M.D, Kanti R. Rai, MD, William G. Wierda, MD, PhD, Andrew Greaves, Laura Z Rassenti, PhD, Donna Neuberg, ScD, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 59.

https://doi.org/10.1182/blood.V116.21.59.59

Published: 2010

Journal Articles

Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model.

Johanna Melo-Cardenas, B.Sc, Mauricio Urquiza, PhD, Robier Aguillon-Prada, M.D, Thomas J. Kipps, MD, PhD, Januario E Castro, M.D

Blood (2010) 116 (21): 1470.

https://doi.org/10.1182/blood.V116.21.1470.1470

Published: 2010

Journal Articles

Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.

Januario E Castro, M.D, Johanna Melo-Cardenas, B.Sc, Juan Sebastian Barajas-Gamboa, M.D, Mauricio Urquiza, PhD, Mark J. Cantwell, PhD, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 1472.

https://doi.org/10.1182/blood.V116.21.1472.1472

Published: 2010

Journal Articles

Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.

Januario E Castro, M.D, Johanna Melo-Cardenas, B.Sc, Juan Sebastian Barajas-Gamboa, M.D, Ramin Sean Pakbaz, M.D, Mauricio Urquiza, PhD, Thomas J. Kipps, MD, PhD

Blood (2010) 116 (21): 1476.

https://doi.org/10.1182/blood.V116.21.1476.1476

Published: 2010

Journal Articles

Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.

Januario E. Castro, M.D., Johanna Melo-Cardenas, B.Sc, Jose Sandoval-Sus, Mauricio Urquiza, Charles Prussak, PhD, Thomas J. Kipps, MD, PhD

Blood (2009) 114 (22): 376.

https://doi.org/10.1182/blood.V114.22.376.376

Published: 2009

Journal Articles

Rituximab and High-Dose Methylprednisolone for the Initial Treatment of Chronic Lymphocytic Leukemia Is Associated with Promising Clinical Activity and Minimal Hematologic Toxicity

Aanelle F James, M.D., Januario E. Castro, M.D., Jose David Sandoval-Sus, M.D., Sonia Jain, Ph.D., Janet Bole, R.N., Laura Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D.

Blood (2008) 112 (11): 47.

https://doi.org/10.1182/blood.V112.11.47.47

Published: 2008

Journal Articles

Rituximab® and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Januario E. Castro, M.D., Jan Bole, R.N., Carlos E. Prada, M.D., Thomas J. Kipps, M.D., Ph.D.

Blood (2004) 104 (11): 2518.

https://doi.org/10.1182/blood.V104.11.2518.2518

Published: 2004

Journal Articles

ZAP-70 Expressed in CLL Is an Hsp90 Client Protein and Its Level of Expression Can Be Downregulated by Specific Hsp90 Inhibitors.

Carlos E. Prada, M.D., Olivier Loria, Adeela Kamal, Ph.D., Francis J. Burrows, Ph.D., Thomas J. Kipps, M.D., Ph.D., Januario E. Castro, M.D.

Blood (2004) 104 (11): 2803.

https://doi.org/10.1182/blood.V104.11.2803.2803

Published: 2004

NARROW

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial

A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

Fd-895 and Pladienolide B Inhibit mRNA Splicing and Induce Apoptosis in Chronic Lymphocytic Leukemia

Heat Shock Protein 90 (Hsp90) Activity Status Is An Independent Prognostic Marker in Chronic Lymphocytic Leukemia (CLL) and Correlates with IgV H Mutational Status, ZAP-70 Expression and Time to First Treatment

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma,

Improved Outcome in Unrelated Donor Recipients After Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Advanced Relapse / Refractory Chronic Lymphocytic Leukemia

Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia

Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy

Ad-ISF35 Intratumoral Administration Induces a Bystander Effect and Immune-Mediated Tumor Rejection with a Safe Vector Biodistribution and Toxicology Profile In a NHL Mouse Model.

Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.

Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.

Ad-ISF35-Transduced Autologous Cells Promote in Vitro and In Vivo Chemosensitization to FCR in Patients with Del(17p) / P53 Defective Chronic Lymphocytic Leukemia.

Rituximab and High-Dose Methylprednisolone for the Initial Treatment of Chronic Lymphocytic Leukemia Is Associated with Promising Clinical Activity and Minimal Hematologic Toxicity

Rituximab® and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

ZAP-70 Expressed in CLL Is an Hsp90 Client Protein and Its Level of Expression Can Be Downregulated by Specific Hsp90 Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only